Tripeptide compound for inhibiting Abeta42 aggregation and reducing cytotoxic effect of Abeta42

• Main Authors: WANG DAYONG, WU ZHONGYUN, YE LIANMENG, YUAN NAN
• Format: Patent
• Language: Chinese; English
• Published: 08.12.2023
• Subjects: CHEMISTRY; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

The invention discloses a tripeptide compound for inhibiting Abeta42 aggregation and reducing the cytotoxic effect of Abeta42. The tripeptide compound comprises ERW or WRR. According to the invention, a tripeptide database is constructed by utilizing a Python language, five tripeptides combined with Abeta42 are screened out through molecular docking, interaction between the five tripeptides (ERW, QRW, RRR, RRW and WRR) and Abeta42 protein is analyzed by utilizing a molecular dynamics method, and the docking conformation of the compound Abeta42-WRR and Abeta42-ERW is displayed to be effective through rationality analysis of a pull diagram structure and analysis of umbrella type sampling binding energy. And the WRR and the ERW have an effective inhibition effect on Abeta42 aggregation. Pharmacological experiments are designed and implemented, and it is verified that WRR, ERW and a compound mixture of WRR and ERW have a good inhibition effect on Abeta42 aggregation, and the cytotoxic effect of secretory-expresse